Genetic testing

2024 Employee Benefit Plans: Focus on Costs, Mental health, Well-being

Retrieved on: 
Monday, January 29, 2024
Standard, Empire Life, Pharmacare, The Conference Board, Business, Government, Mental health, Conference Board of Canada, Genetic testing, Disease, Conference, COVID-19, Pharmacogenomics, Organization, Health

36% ranked cost containment as the top priority—a 17% increase compared to January 2023.

Key Points: 
  • 36% ranked cost containment as the top priority—a 17% increase compared to January 2023.
  • Today's cost-conscious climate makes it especially important for advisors and customers to clarify priorities, said Mark Sylvia, President and CEO of Empire Life.
  • We definitely see an increased emphasis on making sure employees can come to work feeling better, feeling healthy, feeling connected."
  • According to Black, 72% of businesses surveyed had a specific strategy to support mental health and 30% were adopting the National Standard for Psychological Health and Safety.

City of Hope Predicts 8 Important Cancer Trends in 2024

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Managed Care, General Health, Research, Science, Woman, Volunteering, Beckman Research Institute, Biology, Incidence, Prostate cancer, City, Translational Genomics Research Institute, Standard of care, Cancer, Risk, Artificial intelligence, National Cancer Institute, Acceleration, Diagnosis, Medicine, Diabetes, Deana, Stomach cancer, Geography, Irell & Manella, DNA, Policy, Bacteria, Drug development, Virus, Bone marrow, Transport, Organization, Colorectal cancer, Education, Fungus, Physician, Blood, Medicare, Hematology, Immunotherapy, Quality of life, Genetic testing, Millennials, Cell, Mortality, Patient, Federal Medical Centres, Whole genome sequencing, Lung cancer, Triple-negative breast cancer, Immune system

City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.

Key Points: 
  • City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.
  • “City of Hope will soon launch a comprehensive research study validating a blood test developed by researchers at City of Hope and TGen to detect cancers early.
  • Early detection is the key to curing cancer for many,” said Annette Walker, president of City of Hope Orange County.
  • “This is a primary reason City of Hope expanded its National Cancer Institute-designated expertise to Chicago, Phoenix and Atlanta.

Industry-Disrupting Online Cannabis Seed Marketplace Launches in the United States

Retrieved on: 
Friday, January 26, 2024
Seed, Traction, Software, Sale, Genetic testing, Seed bank, Agriculture, Drug

CHICAGO, Jan. 26, 2024 /PRNewswire-PRWeb/ -- Apiary Agriculture Inc. is thrilled to announce the launch of an innovative new cannabis marketplace, Trusted Source, built with powerful software from Arcadier, Pte. Ltd (Arcadier). The platform is set to revolutionize the cannabis industry by providing a seamless way for growers to sell seeds to buyers around the United States.

Key Points: 
  • The most robust cannabis seed platform on the market opens online, utilizing technology developed by a global digital marketplace provider.
  • CHICAGO, Jan. 26, 2024 /PRNewswire-PRWeb/ -- Apiary Agriculture Inc. is thrilled to announce the launch of an innovative new cannabis marketplace, Trusted Source, built with powerful software from Arcadier, Pte.
  • The platform is set to revolutionize the cannabis industry by providing a seamless way for growers to sell seeds to buyers around the United States.
  • The platform is set to revolutionize the cannabis industry by providing a seamless way for growers to sell seeds to buyers around the United States.

SOPHiA GENETICS Supports Genetic Testing in Brazil

Retrieved on: 
Thursday, January 25, 2024
Hope, NGS, DSM-IV codes, Research, Metagenomics, Partnership, Genetics, AI, Genetic testing, GENETICS, Doctor of Philosophy, Sophia Genetics, Data analysis, Medicine, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS' technology to advance and streamline its genetic testing capabilities.

Key Points: 
  • The company will use SOPHiA GENETICS' technology to advance and streamline its genetic testing capabilities.
  • Bioma4me is a leader in Brazil in providing personalized medicine, supported by genetic analysis of each individual, offered at an affordable cost, with great precision and in the shortest possible time.
  • "We are thrilled to announce our collaboration with SOPHiA GENETICS, a leader in AI to further precision medicine.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Susan G. Komen® Pushing for Public Policies to Eliminate Disparities in Breast Care Access

Retrieved on: 
Thursday, January 25, 2024
Mortality, Woman, Cancer, Patient, Public policy, House, Metastatic breast cancer, Legislation, Social, Life, Health equity, Senate, Medicare, Breast cancer, Metastasis, Diagnosis, Social Security Disability Insurance, Breast, MBC, Quality of life, Federation, Genetic testing, Mutation, Disease, Genetics, Access, Birth control

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, is committed to making health care more affordable and accessible to all, by passing state and federal legislation in 2024 to remove barriers that prevent people from receiving the timely and high-quality breast care they need.

Key Points: 
  • Public policies that remove ob­­­­­­stacles, such as the cost of care and when and where care is available, would make an immediate difference in mortality rates.
  • In fact, about one-third of breast cancer deaths could be prevented if everyone received the high-quality care that exists today.
  • Breast imaging, the most effective tool at detecting breast cancers, is available to most people yet is not accessible to all.
  • "Komen is approaching breast cancer comprehensively through diverse public policy initiatives, aiming to minimize the number of breast cancer deaths," Guthrie added.

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Retrieved on: 
Tuesday, January 23, 2024
Child, Hearing loss, Lilly, Clinical trial, Gene, Medicine, Sant Joan, ABR, Eli Lilly and Company, Genetic testing, Division, HL, Hospital, ARO, FDA, Physician, Late, Hearing, Research, Diagnosis, LLY, SVP, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss. Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.

Key Points: 
  • Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.
  • Both the surgical administration procedure and the investigational therapy were well tolerated, and no serious adverse events were reported.
  • Millions of individuals worldwide have disabling hearing loss because one of their genes generates an incorrect or incomplete version of a protein the ear requires for hearing.
  • OTOF-mediated hearing loss is the first monogenic form of hearing loss to be investigated as part of a gene therapy clinical trial.

National Center for Children's Vision and Eye Health at Prevent Blindness Celebrates 15th Anniversary in 2024

Retrieved on: 
Tuesday, January 23, 2024
Retina, Learning, Research, Public policy, Life, Mother, School, Science, Child, Prevention, Public, Genetic testing, Doctor of Education, Public health, ROP, Vision, Human services, DSM-IV codes, Parent, Optometry and Vision Science, Visual impairment, EST, Education, Author, Birth control

CHICAGO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- The National Center for Children's Vision and Eye Health at Prevent Blindness (NCCVEH) is celebrating its 15th Anniversary in 2024. Throughout the year, the NCCVEH will be providing a variety of free resources to parents, partner organizations, and healthcare professionals, in a celebration of its 15 years of raising awareness and providing essential information on the best ways to help put children on the path to a lifetime of healthy vision.

Key Points: 
  • The National Center for Children's Vision and Eye Health at Prevent Blindness to Commemorate 15th Anniversary Milestone by Launching a Year-long Series of Webinars, Blogs, Educational Activities, And More, to Promote Healthy Vision for Kids
    CHICAGO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- The National Center for Children's Vision and Eye Health at Prevent Blindness (NCCVEH) is celebrating its 15th Anniversary in 2024.
  • "Today, the NCCVEH is a trusted source of information and a respected convenor of all stakeholders in children's vision and eye health including public health, eye care, health care, early childhood education and care, schools, and families."
  • "The positive impact of the National Center for Children's Vision and Eye Health at Prevent Blindness over the past 15 years has been profound.
  • "Promoting improvements for vision and eye health in all components of the system results in better vision health, more empowered families, and reduced eye health disparities.

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

Retrieved on: 
Tuesday, January 23, 2024
Fertility, Infertility, Health, IVF, Partnership, Female, Male, Menopause, Workplace, Genetic testing, Trusted Partner, Education, ACCD, Birth control

SEATTLE, Jan. 23, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Kindbody, a technology-driven fertility clinic network and family-building benefits provider for employers, will join the company's Trusted Partner Ecosystem to offer Accolade customers comprehensive, clinically guided support and care throughout a member's fertility and family-building journey, all backed by a new cost savings performance guarantee.

Key Points: 
  • Kindbody addresses these issues by providing affordable fertility care and delivering a seamless, integrated experience with best-in-class outcomes.
  • Kindbody delivers this model through a combination of owned and operated signature clinics and hundreds of partner clinics nationwide.
  • Joint customers of Accolade and Kindbody will benefit from integrations designed to promote awareness of Kindbody's services, at no incremental cost to customers.
  • Launched in 2019, Accolade's Trusted Partner Ecosystem is the first in the industry to bring together multiple benefits solutions across valued categories, making them available to employers through a single front door.

OVARIAN CANCER RESEARCH ALLIANCE CELEBRATES LANDMARK YEAR OF ACHIEVEMENTS IN 2023, SURPASSING FUNDRAISING GOALS AND ACCELERATING RESEARCH IN GYNECOLOGIC CANCERS

Retrieved on: 
Wednesday, January 17, 2024
Patient, Ovarian cancer, Research, Congress, OCRA, Life, Knowledge, Medicare, Data wrangling, Survivor, Cancer, Risk, Quality of life, Oncology nursing, Genetic testing, Human, Ovarian Cancer Research Alliance, Ovary, Diagnosis, Birth control

"Historically, 2023 has been a year of unparalleled achievement for OCRA," said Audra Moran, President and CEO.

Key Points: 
  • "Historically, 2023 has been a year of unparalleled achievement for OCRA," said Audra Moran, President and CEO.
  • "Our achievements this year have bolstered our commitment and energized our efforts to drive significant progress in understanding, preventing, and treating ovarian and related gynecologic cancers."
  • Recognizing the interconnectedness of ovarian and related gynecologic cancers, OCRA expanded its mission accelerating progress, acknowledging commonalities between these diseases, and broadening our impact on patients' lives.
  • Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to advancing ovarian cancer research while supporting patients and their families.

Hyris Fulfils Its Integration Into Ulisse Biomed to Give Birth to a New International Group Ready to Make Its Mark in the Global Biotech Market

Retrieved on: 
Monday, January 15, 2024
Genetic testing, UBM, Molecular biology, Health

The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.

Key Points: 
  • The new group, strong of flawless interoperability between its leading technologies, aims to become a new benchmark of innovation in the national and international biotech market.
  • By joining forces, we will enhance our product offering, combining our experience and development capabilities with Hyris' unique mix of competencies.
  • Stefano Lo Priore, founder of Hyris and former CEO and recently appointed Chairman of UBM Group, agrees: "We are proud of this integration between Ulisse Biomed and Hyris.
  • We are ready for the challenges that await us, strong of the competencies that the two companies will be able to pool together."